Shares of biotech firm Mersana Therapeutics (MRSN Quick QuoteMRSN - Free Report) soared on Wednesday, closing up 69% to $18.19 per share.

Mersana reported positive interim results of an early-stage study of XMT-1536, an antibody-drug conjugate for treatment of patients with ovarian cancer. 10% of patients experienced complete remission after taking XMT-1536, while others achieved a 35% objective response rate. This means they saw tumor reduction by a pre-determined amount.

The drug candidate also has a good safety profile. CEO Anna Protopapas said the drug was “generally well tolerated”

Mersana is planning on reporting additional data from the study in the second half of 2020, which could be another big driver for the stock.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.

Click here for the 6 trades >>